AGT and diabetic kidney disease: The Reduction in Endpoints in Non-insulin-dependent DM with the Angiotensin II Antagonist Losartan (RENAAL) study demonstrated the renal-protective effect of losartan in patients with diabetic nephropathy, which resulted in the reduction of proteinuria and an improvement in cardiovascular outcomes [29].